Evidence map›Paper›PMID 37220815›Full record

Trial reportOphthalmology2023

SCORE2 Report 24: Nonlinear Relationship of Retinal Thickness and Visual Acuity in Central Retinal and Hemiretinal Vein Occlusion.

Ingrid U Scott, Neal L Oden, Paul C VanVeldhuisen, Michael S Ip, Barbara A Blodi, SCORE2 Investigator Group

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Ingrid U ScottDepartments of Ophthalmology and Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania.
Neal L OdenEmmes, Rockville, Maryland.
Paul C VanVeldhuisenEmmes, Rockville, Maryland. Electronic address: score2@emmes.com.
Michael S IpDoheny Eye Institute, University of California, Los Angeles, Los Angeles, California.
Barbara A BlodiUniversity of Wisconsin Fundus Photograph Reading Center, Madison, Wisconsin.
SCORE2 Investigator Group
Emmes (United States) · USPenn State Milton S. Hershey Medical Center · USUniversity of California, Los Angeles · USUniversity of Wisconsin Foundation · US

Funding

SCORE2 Comparative Trial (SCT)U10EY023533 · NEI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI SCOTT, INGRID U · 2013 to 2018
$7.4M
SCORE2 Comparative Trial (SCT)U10EY023529 · NEI · THE EMMES COMPANY, LLC · PI VAN VELDHUISEN, PAUL C · 2013 to 2018
$6.8M
The SCORE2 Long-Term Follow-Up (SCORE2 LTF)UG1EY023533 · NEI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI SCOTT, INGRID U · 2019 to 2021
$3.7M
SCORE2 Comparative Trial (SCT)U10EY023521 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI BLODI, BARBARA A · 2013 to 2018
$1.8M
NEI NIH HHS U10 EY023521NEI NIH HHS U10 EY023529NEI NIH HHS U10 EY023533NEI NIH HHS UG1 EY023533
6 · The paper itself

Abstract

purposeTo investigate whether a nonlinear association between central subfield thickness (CST) on spectral-domain OCT and concurrent visual acuity letter score (VALS) exists in eyes treated initially with aflibercept or bevacizumab for macular edema associated with central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO) in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2).

designLong-term follow-up after a randomized clinical trial from 64 centers in the United States.

participantsParticipants were followed up to 60 months and treated at investigator discretion after completing the 12-month treatment protocol.

methodsTwo-segment linear regression models were compared with simple linear regression models of VALS on CST. Pearson correlation coefficients were calculated to assess strength of CST and VALS associations.

main outcome measuresCentral subfield thickness was measured by OCT and VALS by the electronic Early Treatment Diabetic Retinopathy Study methodology.

resultsEstimated inflection points, reflecting turning points at which the CST and VALS association changes from positive to negative, calculated at 7 postbaseline visits, range from 217 to 256 μm. A strongly positive correlation exists to the left of each estimated inflection point, ranging from 0.29 (P < 0.01 at month 60) to 0.50 (P < 0.01 at month 12), and a strongly negative correlation exists to the right of each estimated inflection point, ranging from -0.43 (P < 0.01 at month 1) to -0.74 (P < 0.01 at month 24). Randomization statistical tests showed that 2-segment models are favored over 1-segment models for all postbaseline months (P < 0.001 for all tests performed).

conclusionsThe relationship between CST and VALS in eyes with CRVO or HRVO after treatment with anti-vascular endothelial growth factor (VEGF) therapy is not simply linear. The usually modest correlations between OCT-measured CST and visual acuity belie strong left and right correlations present in 2-segment models. Post-treatment CST close to the estimated inflection points showed the best expected VALS. The SCORE2 participants with a post-treatment CST after treatment close to the estimated inflection points of 217 to 256 μm showed the best VALS. In patients treated with anti-VEGF for macular edema associated with CRVO or HRVO, a thinner retina is not always associated with better VALS. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Indexed as

Macular EdemaRetinal Vein OcclusionAngiogenesis InhibitorsBevacizumabHumansIntravitreal InjectionsRetinaTomography, Optical CoherenceValsartanVisual AcuityAngiogenesis InhibitorsBevacizumabValsartanAnti-VEGF treatmentCentral retinal vein occlusionCentral subfield thickness visual acuityHemiretinal vein occlusion

Identifiers

PMID37220815
PMCPMC10524366
OpenAlexW4377195287

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.